The study evaluated the efficacy and safety of investigational therapy CC-486 as maintenance therapy in patients with newly diagnosed acute myeloid leukemia (AML) who achieved first complete response The post Celgene’s QUAZAR AML-001 trial of CC-486 meets primary and key secondary endpoints appeared first on Pharmaceutical Business review.
This initial consideration to Innovus common shareholders is estimated to consist of approximately 4.2 million shares of Aytu stock. Additional consideration for up to $16 million in milestone The post Aytu BioScience to acquire Innovus Pharmaceuticals appeared first on Pharmaceutical Business review.
Nucala is claimed to be the only targeted biologic to secure approval for the condition in the six to 11-year age group in the US. The FDA approval The post FDA approves GSK’s Nucala for young children with severe eosinophilic asthma appeared first on Pharmaceutical Business review.
As part of the collaboration, VBI plans to add an additional study arm to Part B of the company’s ongoing, multi-center, open-label Phase 1/2a clinical study targeting recurrent The post VBI Vaccines announces phase 2a trial of VBI-1901 plus AS01B adjuvant system in recurrent glioblastoma appeared first on Pharmaceutical Business review.
Scientific teams from Atomwise and Hansoh Pharma will work closely together on the programs. The combination of complementary expertise and technologies has the potential to dramatically increase success The post Hansoh Pharma, Atomwise launch AI drug discovery collaboration for multiple therapeutic areas appeared first on Pharmaceutical Business review.
The trial is evaluating Tecentriq as a first-line (initial) monotherapy compared against cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung The post Roche’s Tecentriq monotherapy significantly improves OS in phase III lung cancer study appeared first on Pharmaceutical Business review.
GVOKE is a ready-to-use, room-temperature stable liquid glucagon product, which can be administered to the patient using a prefilled syringe or auto-injector. The liquid glucagon product will be The post FDA approves Xeris’ GVOKE injection for treatment of severe hypoglycaemia appeared first on Pharmaceutical Business review.
“Evobrutinib is a potential innovation for people living with MS, as it may offer a novel dual mechanism of action that is thought to impact myeloid cells in The post Merck initiates phase 3 programme for evobrutinib in relapsing multiple sclerosis appeared first on Pharmaceutical Business review.
Sitari has been developing a novel treatment for celiac disease and was the first company formed under the GSK-Avalon venture collaboration in 2013. Sitari was incubated at COI The post Avalon Ventures and COI Pharmaceuticals announce acquisition of Sitari Pharmaceuticals by GSK appeared first on Pharmaceutical Business review.
The ASPIRE I and II trials evaluated the efficacy and safety of esketamine nasal spray in 465 patients with the moderate-to-severe major depressive disorder who have active suicidal The post Esketamine nasal spray reduces depressive symptoms in two phase 3 studies appeared first on Pharmaceutical Business review.